CARISMA Therapeutics Inc (CARM)
1.25
+0.10
(+8.70%)
USD |
NASDAQ |
Jun 26, 13:49
CARISMA Therapeutics Revenue (Quarterly): 3.397M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.397M |
| December 31, 2023 | 4.289M |
| September 30, 2023 | 3.827M |
| June 30, 2023 | 3.56M |
| March 31, 2023 | 3.243M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.731M |
| September 30, 2022 | 2.578M |
| June 30, 2022 | 2.703M |
| March 31, 2022 | 0.822M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.822M
Minimum
Mar 2022
4.289M
Maximum
Dec 2023
3.128M
Average
3.397M
Median
Mar 2024
Revenue (Quarterly) Benchmarks
| Verastem Inc | -- |
| Aquestive Therapeutics Inc | 12.05M |
| Gritstone Bio Inc | 0.049M |
| Black Diamond Therapeutics Inc | -- |
| Moderna Inc | 167.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -18.98M |
| Total Expenses (Quarterly) | 22.91M |
| EPS Diluted (Quarterly) | -0.46 |
| Enterprise Value | -9.572M |
| Profit Margin (Quarterly) | -558.7% |
| Earnings Yield | -156.8% |
| Normalized Earnings Yield | -156.80 |